Ignite Creation Date:
2025-12-24 @ 5:39 PM
Ignite Modification Date:
2026-01-04 @ 2:19 PM
Study NCT ID:
NCT06408168
Status:
TERMINATED
Last Update Posted:
2025-12-15
First Post:
2024-04-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-08
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-08
Completion Date Type:
ACTUAL
First Submit Date:
2024-04-30
First Submit QC Date:
None
Study First Post Date:
2024-05-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-09
Last Update Post Date:
2025-12-15
Last Update Post Date Type:
ESTIMATED